Table 2.
Targeted treatment regimens for mCRC.
| Molecular Target | Targeted Therapy | Approved or Trial Reference | Treatment Regimens |
|---|---|---|---|
| EGFR | Cetuximab | Approved | FOLFIRI + Cetuximab |
| Cetuximab | NCT01228734 | *FOLFOX *FOLFOX + Cetuximab |
|
| Cetuximab | EPIC | *Irinotecan *Irinotecan + Cetuximab |
|
| Panitumumab | NCT00364013 | *FOLFOX *FOLFOX + Panitumumab |
|
| Panitumumab | NCT00339183 | *FOLFIRI *FOLFIRI + Panitumumab |
|
| Panitumumab | NCT03231722 | *FOLFOX +Cetuximab *FOLFIRI + Panitumumab |
|
| VEGF | Bevacizumab | Approved | FOLFIRI + Bevacizumab |
| Bevacizumab | NCT00719797 | *FOLFOX +Bevacizumab *FOLFIRI + Bevacizumab |
|
| Bevacizumab | NCT00484939 | *Capecitabine *Bevacizumab + Capecitabine |
|
| Afibercept | NCT01661270 | *FOLFIRI *FOLFIRI + Afibercept |
|
| Receptor Tyrosine Kinase and KRAS | Regorafenib | NCT 04117945 | *Regorafenib + Cetuximab/Panitumumab * Cetuximab/ Panitumumab + Regorafenib |
| Regorafenib | NCT03844620 | CTCs as an indicator of treatment response to Regorafenib |
|
| Regorafenib | NCT03657641 | Regorafenib + Pembrolizumab | |
| Regorafenib | NCT04362839 | Regorafenib + Ipilimumab + Nivolumab | |
| MRTX849 | NCT03785249 | *MRTX849 *MRTX849 + Cetuximab *MRTX849 + Pembrolizumab *MTRX849 + Afatinib |
A summary of targeted treatment regimens approved or in clinical trials for mCRC. This summary is not exhaustive, however provides an overview of some of the key treatment regimens available in the clinic.